DWM
BLPH

Destination Wealth Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Destination Wealth Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$78.9K – 230
2023
Q1 		$78.9K Hold
10,000
– – ﹤0.01% 203
2022
Q4 		$9K Hold
10,000
– – ﹤0.01% 199
2022
Q3 		$11K Hold
10,000
– – ﹤0.01% 186
2022
Q2 		$12K Buy
+10,000
New +$13.4K ﹤0.01% 192

Other funds holding BLPH

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Destination Wealth Management's BLPH Position: Q2 2023 in Review

Destination Wealth Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2023, closing a stake of 10,000 shares — an estimated $78.9K sold.

Destination Wealth Management first reported a position in BLPH in Q2 2022 and held it in 4 quarters. The position peaked at $78.9K in Q1 2023. 23 funds tracked by Wall St. Rank hold BLPH as of Q2 2023.

  • Destination Wealth Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Destination Wealth Management sold 10,000 Bellerophon Therapeutics, Inc. shares in Q2 2023, an estimated $78.9K.
  • Destination Wealth Management first reported a position in Bellerophon Therapeutics, Inc. in Q2 2022 and held it in 4 quarters.
  • Destination Wealth Management's Bellerophon Therapeutics, Inc. position peaked at $78.9K in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2023.

Based on Destination Wealth Management's 13F filing for Q2 2023, filed 11 Aug 2023.